News

GLEN BURNIE // January 31, 2024 - Diagnostic Biochips is pleased to announce the appointment of Allen Waziri, MD, Co-Founder and CEO of iCE Neurosystems, to its Board of Directors.

Diagnostic Biochips Inc. is pleased to announce Green Leaf Scientific as our new European representative for our full line of miniaturized high-channel-count probes for recording circuit-level neural activity. Diagnostic Biochips smaller, less invasive, technology shows great promise in the fields of pre-clinical neuroscience, brain-computer interface, and human clinical applications.

Scott Smith is a neurotechnology executive who has enthusiastically embraced innovation in the fields of cognitive and clinical neuroscience and neurology for over 25 years. Scott was part of the team who brought the first commercial 128 channel amplifier to market (Neuroscan Synamp), and the first FDA approved 512 channel system for recording from microelectrodes in humans (Neuralynx ATLAS). He has extensive expertise in equipping pre-clinical research studies, including human single-neuron studies. Scott is passionate about enabling research by neuroscientists and clinicians at many of the...

A new paper from the Long Lab demonstrates the importance of axonal delays in shaping the dynamical repertoire of neural activity, even within the context of local microcircuits. Read the entire paper here.

Diagnostic Biochips’ Brian G. Jamieson PhD co-authored “Multichannel Silicon Probes for Awake Hippocampal Recordings in Large Animals” with Alexandra V. Ulyanova, Carlo Cottone, Christopher D. Adam, Kimberly G. Gagnon, D. Kacy Cullen, Tahl Holtzman, Paul F. Koch, H. Isaac Chen, Victoria E. Johnson, and John A. Wolf. The research article was published in the Neural Technology section of Frontiers in Neuroscience on April 26, 2019.

Diagnostic BioChips was awarded a $1.8M grant to further develop its technology for continuous in vivo monitoring of IL-6 for the early detection of sepsis or cytokine storm syndrome.

TEDCO (Technology Development Corporation of MD) has awarded DBC a grant to support the cost of regulatory consulting for preparing our first FDA submission for the continuous monitoring of doxorubicin in the bloodstream of chemotherapy patients.

A two-year agreement was signed with the UK-based distributor Cambridge Neurotech (CNT.) CNT will sell DBC’s proprietary “Neural Mapping Microsensor (NMM)” in Europe and the US. NMM is a research tool that offers unprecedented capabilities for continuous real-time monitoring of small populations of active neurons in the brain or peripheral nervous system.